

Dolores Grosso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3177929/publications.pdf>

Version: 2024-02-01

18
papers

176
citations

1683934

5
h-index

1372474

10
g-index

18
all docs

18
docs citations

18
times ranked

352
citing authors

#	ARTICLE	IF	CITATIONS
1	A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. <i>Blood</i> , 2011, 118, 4732-4739.	0.6	71
2	A Two-Step Approach to Myeloablative Haploidentical Transplantation: Low Nonrelapse Mortality and High Survival Confirmed in Patients with Earlier Stage Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 646-652.	2.0	41
3	A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 141-148.	2.0	29
4	Evaluating frequency and quality of pathogen-specific T cells. <i>Nature Communications</i> , 2016, 7, 13264.	5.8	12
5	A Two-Step Approach to Allogeneic Haploidentical Hematopoietic Stem Cell Transplantation. <i>Seminars in Oncology</i> , 2012, 39, 694-706.	0.8	10
6	An Examination of Cytomegalovirus, Socioeconomic Status, Race, and Ethnicity on Outcomes after Haploidentical Hematopoietic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 327.e1-327.e11.	0.6	4
7	Relapsed Multiple Myeloma Presenting as Intracranial Plasmacytoma and Malignant Pericardial Effusion following Recent Allogeneic Stem Cell Transplantation. <i>Case Reports in Oncology</i> , 2017, 10, 582-587.	0.3	2
8	Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non-Cyclophosphamide-Exposed T Cells on Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1861-1867.	2.0	2
9	The Two-Step Allogeneic Stem Cell Transplantation Approach Results in Rapid Engraftment and Excellent Outcomes in Patients with Lymphoid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 159.e1-159.e5.	0.6	2
10	Posttreatment interleukin-2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?. <i>Cancer</i> , 2014, 120, 940-941.	2.0	1
11	COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience. <i>Blood</i> , 2020, 136, 36-37.	0.6	1
12	Vaccination Response after Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 25-26.	0.6	1
13	A Two Step Myeloablative Approach to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Hematological Malignancies From HLA Partially-Matched (Haploidentical) Related Donors.. <i>Blood</i> , 2009, 114, 2292-2292.	0.6	0
14	2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach. <i>Blood</i> , 2018, 132, 4661-4661.	0.6	0
15	Design and Implementation of a Multipurpose Information System for Hematopoietic Stem-Cell Transplantation on the Basis of the Biomedical Research Integrated Domain Group Model. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1076-1084.	1.0	0
16	The Two-Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation (HI HSCT): 15 Years of Transplants in Patients 19-78 Years Old. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
17	Encouraging Results of Haploidentical Transplantation in Older Patients Using the Two-Step T Cell Tolerization Platform - Results of a Prospective Trial. <i>Blood</i> , 2020, 136, 40-40.	0.6	0
18	High Survival in Patients with Myelofibrosis Undergoing a Two-Step Approach to Hematopoietic Stem Cell Transplantation (HSCT): Effects of Donor Source and Pre-HSCT Splenic Therapy on Outcomes. <i>Blood</i> , 2020, 136, 37-38.	0.6	0